(Q36675446)

15 August 2017

1 reference

title

Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors (English)

1 reference

15 August 2017

Steve H Thorne

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

41-51

1 reference

Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Overview of interleukin-2 as an immunotherapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Monoclonal and bispecific antibodies as novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Stem cells and cancer: an intimate relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Adenovirus p53 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Introduction to the background, principles, and state of the art in suicide gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Tumor vascular targeting therapy with viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Recent progress in the battle between oncolytic viruses and tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Newcastle disease virus selectively kills human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Oncolytic viral therapies - the clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

A role for the PDZ-binding domain of the coxsackie B virus and adenovirus receptor (CAR) in cell adhesion and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Scavenger receptors in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Intravenous immunoglobulin: production, uses and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Pox viral vaccine approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

On the road to a tumor cell vaccine: 20 years of cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Immune cell migration in inflammation: present and future therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Therapeutic applications for hematopoietic stem cell gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Synergistic antitumor effects of immune cell-viral biotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

Effect of Histolyticus Infection and Toxin on Transplantable Mouse Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.41

21 January 2018

Identifiers

DOI

10.1517/14712598.7.1.41

1 reference

15 August 2017

1 reference